These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 773824)

  • 21. THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO.
    WARD PA; COCHRANE CG; MUELLER-EBERHARD HJ
    J Exp Med; 1965 Aug; 122(2):327-46. PubMed ID: 14316948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of the inhibition of chemotaxis by phosphonate esters.
    Ward PA; Becker EL
    J Exp Med; 1967 Jun; 125(6):1001-20. PubMed ID: 4164884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological studies of anergic patients.
    Van Epps DE; Frierson JA; Williams RC
    Infect Immun; 1974 Nov; 10(5):1003-9. PubMed ID: 16558080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotaxis of basophils by lymphocyte-dependent and lymphocyte-independent mechanisms.
    Ward PA; Dvorak HF; Cohen S; Yoshida T; Data R; Selvaggio SS
    J Immunol; 1975 May; 114(5):1523-31. PubMed ID: 1091704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutrophil chemotaxis and serum chemotactic activity in systemic lupus erythematosus.
    Alvarez I; Vazquez JJ; Fontan G; Gil A; Barbado J; Ojeda JA
    Scand J Rheumatol; 1978; 7(2):69-74. PubMed ID: 705269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different concentrations of chemotactic factors can produce attraction or migration inhibition of leukocytes.
    Jungi TW
    Int Arch Allergy Appl Immunol; 1977; 53(1):29-36. PubMed ID: 838513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of eosinophil leukocyte chemotaxis by a factor in normal human serum (SEF).
    Czarnetzki BM
    Int Arch Allergy Appl Immunol; 1979; 60(3):315-24. PubMed ID: 489135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of chemotactic activity of human polymorphonuclears by monoclonal IgMs with and without biological activity.
    Pruzanski W; Nitzan DW; Saito S
    Am J Hematol; 1986 Sep; 23(1):31-42. PubMed ID: 3090874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum-mediated stimulation and inhibition of neutrophil locomotion in sarcoidosis.
    Schmekel B; Håkansson L; Hällgren R; Stålenheim G; Venge P
    Eur J Respir Dis; 1984 Nov; 65(8):592-9. PubMed ID: 6519214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of chemotactic factors with human macrophages. Induction of transmembrane potential changes.
    Gallin EK; Gallin JI
    J Cell Biol; 1977 Oct; 75(1):277-89. PubMed ID: 410816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defective polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis associated with a serum inhibitor.
    Hanlon SM; Panayi GS; Laurent R
    Ann Rheum Dis; 1980 Feb; 39(1):68-74. PubMed ID: 6990882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of chemotaxis of neutrophil leukocytes to interleukin-8 by endotoxins of various bacteria.
    Bignold LP; Rogers SD; Siaw TM; Bahnisch J
    Infect Immun; 1991 Nov; 59(11):4255-8. PubMed ID: 1937782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum inhibitory factor for guinea pig macrophage and neutrophil chemotaxis found in cancer patients.
    Miyahara T; Torisu M
    Gan; 1981 Dec; 72(6):854-61. PubMed ID: 7341335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet-dependent generation of chemotactic activity in serum.
    Weksler BB; Coupal CE
    J Exp Med; 1973 Jun; 137(6):1419-30. PubMed ID: 4709268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial analysis and purification of polymorphonuclear neutrophil chemotactic inhibitors in serum from anergic patients.
    Christou NV; Meakins JL
    Arch Surg; 1983 Feb; 118(2):156-60. PubMed ID: 6849633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotactic activity in dialyzable transfer factor.
    Gallin JI; Kirkpatrick CH
    Proc Natl Acad Sci U S A; 1974 Feb; 71(2):498-502. PubMed ID: 4205594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infection in patients with systemic lupus erythematosus. Association with a serum inhibitor of complement-derived chemotactic activity.
    Perez HD; Andron RI; Goldstein IM
    Arthritis Rheum; 1979 Dec; 22(12):1326-33. PubMed ID: 518715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psoriasis and leukocyte chemotaxis.
    Tagami H; Iwatsuki K; Takematsu H
    J Invest Dermatol; 1987 Mar; 88(3 Suppl):18s-23s. PubMed ID: 3493302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CiC3-1a-mediated chemotaxis in the deuterostome invertebrate Ciona intestinalis (Urochordata).
    Pinto MR; Chinnici CM; Kimura Y; Melillo D; Marino R; Spruce LA; De Santis R; Parrinello N; Lambris JD
    J Immunol; 2003 Nov; 171(10):5521-8. PubMed ID: 14607959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotaxis of polymorphonuclear leukocytes in response to surface-bound complement-derived chemoattractants generated in situ.
    Dahlgren C; Hed J; Stendahl O
    Inflammation; 1984 Jun; 8(2):201-8. PubMed ID: 6378792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.